Trichomonas Vaginalis

2261 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Trichomonas written for patients

Trichomonas vaginalis is a very common sexually transmitted infection (STI) that can cause vaginitis, cervicitis and urethritis.

  • T. vaginalis is a flagellated protozoan.
  • T. vaginalis is a member of the Parabasalia, a group of single-celled eukaryotes within the clade Excavata, which also includes parasites of genera such as Giardia and Trypanosoma.[1] 
  • In women the organism is found in the vagina, urethra and paraurethral glands.
  • Urethral infection is present in 90% of infected women.[2] 
  • In men infection is usually of the urethra.
  • In adults transmission is almost exclusively through sexual intercourse.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »
  • T. vaginalis is the most common curable STI worldwide.[3] 
  • Despite having the highest prevalence of any STI globally, there is a dearth of data describing T. vaginalis incidence and prevalence in the general population.[4] 
  • T. vaginalis is still underdiagnosed and therefore undertreated.

Women

  • The symptoms of T. vaginalis can be confused with bacterial vaginosis (BV).
  • Around 70% of women have a vaginal discharge.
  • Although this is usually a frothy yellowish discharge, it can vary from being thin and scanty to profuse and thick.
  • Other common symptoms include vulval itching, dysuria or offensive odour.
  • Lower abdominal discomfort can occur in some women.
  • There may be signs of local inflammation with vulvitis and vaginitis.
  • Cervicitis may be present which leads to the cervix having the appearance of the surface of a strawberry; sometimes referred to a 'strawberry cervix'.
  • 10-50% of women will have no symptoms and 5-15% of women will have a normal examination.[2] 

Men

  • Men are usually asymptomatic.
  • T. vaginalis is increasingly being recognised as a cause of non-gonococcal urethritis.[5] 
  • The most common symptoms are dysuria and presence of a urethral discharge.
  • The vast majority of men will have no abnormal signs on examination.
  • If T. vaginalis is suspected, a high vaginal swab can be taken from the posterior fornix but sensitivity may be low because motility reduces with transit time.
  • Self-administered vaginal swabs are increasingly being performed.
  • Referral to a genitourinary clinic is therefore recommended for confirmation by wet microscopy which should be read within 10 minutes of collection.[6] 
  • Laboratories may not routinely perform wet microscopy or T. vaginalis culture so suspected T. vaginalis should be mentioned on the laboratory request form.
  • Women with suspected T. vaginalis should also have contact tracing undertaken.
  • Women with T. vaginalis need testing for other STIs.
  • Urethral culture or culture of first-void urine will diagnose 60-80% of cases in men.
  • Test of cure is only recommended if symptoms persist or recur.
  • Screening of asymptomatic people (including those who are pregnant) is currently not recommended.
  • Nucleic acid amplification tests (NAATs) offer the highest sensitivity for the detection of T. vaginalis. They should be the test of choice where resources allow and are becoming the current gold standard.[2] 
  • Both partners should ideally be treated at the same time.
  • Sexual intercourse should be avoided for at least one week following receiving treatment.
  • All patients should receive clear and accurate written information about this condition.
  • Although TV is easily treated with metronidazole in most cases, resistant strains are on the increase.[7] .
  • Systemic treatments are far more effective than topical treatments and include:
    • Oral metronidazole 2 g as a single dose.
    • Oral metronidazole 400 mg to 500 mg bd for five to seven days.
    • Oral tinidazole 2 g single dose can be given as an alternative if metronidazole is not effective.
  • Treatment of partners is recommended, regardless of their results.

NB: Metronidazole can be used in all stages of pregnancy and during breast-feeding. Although symptomatic women should be treated at diagnosis, some clinicians have preferred to defer treatment until the second trimester. High-dose regimens are not recommended to be taken during pregnancy.[8] The manufacturers recommend avoiding high doses if breast-feeding or, if using a single dose of metronidazole, breast-feeding should be discontinued for 12-24 hours to reduce infant exposure. Tinidazole should be avoided during pregnancy.

Complications of T. vaginalis include:

  • Preterm delivery and low birth weight.[3] 
  • T. vaginalis infection at delivery may predispose to maternal postpartum sepsis.
  • There is growing evidence that trichomoniasis infection may enhance HIV transmission.
  • There may be an increased risk of T. vaginalis infection in those people who are HIV-positive.[9] 
  • Persistent and recurrent T. vaginalis infections are frequent in women, potentially due to the lack of routine screening recommendations for this pathogen, the chronic nature of some infections and also drug resistance.[10] 
  • Prostatitis can occasionally occur in men.

Further reading & references

  1. Land KM, Wrischnik LA; Basic biology of Trichomonas vaginalis: current explorations and future directions. Sex Transm Infect. 2013 Sep;89(6):416-7. doi: 10.1136/sextrans-2013-051153.
  2. Management of trichomonas vaginalis; British Asociation of Sexual Health and HIV (Feb 2014)
  3. Silver BJ, Guy RJ, Kaldor JM, et al; Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014 Jun;41(6):369-76. doi: 10.1097/OLQ.0000000000000134.
  4. Poole DN, McClelland RS; Global epidemiology of Trichomonas vaginalis. Sex Transm Infect. 2013 Sep;89(6):418-22. doi: 10.1136/sextrans-2013-051075. Epub 2013 Jun 6.
  5. Muzny CA, Schwebke JR; The clinical spectrum of Trichomonas vaginalis infection and challenges to management. Sex Transm Infect. 2013 Sep;89(6):423-5. doi: 10.1136/sextrans-2012-050893. Epub 2013 Mar 30.
  6. Gaydos C, Hardick J; Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert Rev Anti Infect Ther. 2014 Jun;12(6):657-72. doi: 10.1586/14787210.2014.880651. Epub 2014 Feb 3.
  7. Kusdian G, Gould SB; The biology of Trichomonas vaginalis in the light of urogenital tract infection. Mol Biochem Parasitol. 2014 Dec;198(2):92-9. doi: 10.1016/j.molbiopara.2015.01.004. Epub 2015 Feb 9.
  8. British National Formulary; 69th Edition (Mar 2015) British Medical Association and Royal Pharmaceutical Society of Great Britain, London
  9. Alcaide ML, Feaster DJ, Duan R, et al; The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect. 2015 Jun 12. pii: sextrans-2015-052010. doi: 10.1136/sextrans-2015-052010.
  10. Sena AC, Bachmann LH, Hobbs MM; Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther. 2014 Jun;12(6):673-85. doi: 10.1586/14787210.2014.887440. Epub 2014 Feb 20.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Louise Newson
Current Version:
Peer Reviewer:
Dr Hayley Willacy
Document ID:
29065 (v1)
Last Checked:
23/06/2015
Next Review:
21/06/2020

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

 
 
Patient Access app - find out more Patient facebook page - Like our page